Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

FGFR4

RBC: FGFR4 · Substrate: pEY + Mn ·

Top inhibitors

MeasuredDerived
DrugInhibition %Gini
Erdafitinib98.00.74
Futibatinib97.90.72
Alpelisib96.80.72
Ponatinib96.70.53
Infigratinib94.70.71
Pemigatinib93.90.72
Deucravacitinib92.00.72
Tenalisib83.90.70
Lenvatinib79.30.73
Brigatinib73.30.51
Pralsetinib64.60.64
Tepotinib49.20.73
Selpercatinib49.10.64
Ceritinib48.20.62
Pazopanib43.10.67

Known variants

Cancer associations

MutationCancer typeOrganSource
N535Kcarcinoma_breastBreasthttps://doi.org/10.1093/nar/gkaa945
N535Kcarcinoma_pancreasPancreashttps://doi.org/10.1093/nar/gkaa945
N535Krhabdomyosarcoma_soft_tissueSoft Tissuehttps://doi.org/10.1093/nar/gkaa945
N535Kcarcinoma_large_intestineLarge Intestinehttps://doi.org/10.1093/nar/gkaa945
N535Kcarcinoma_liverLiverhttps://doi.org/10.1093/nar/gkaa945
N535Ksex_cord-stromal_tumour_testisGenitourinary systemhttps://doi.org/10.1093/nar/gkaa945
V550Lrhabdomyosarcoma_soft_tissueSoft Tissuehttps://doi.org/10.1093/nar/gkaa945
V550Lcarcinoma_breastBreasthttps://doi.org/10.1093/nar/gkaa945
V550Lmalignant_fibrous_histiocytoma-pleomorphic_sarcoma_soft_tissueSoft Tissuehttps://doi.org/10.1093/nar/gkaa945
V550Lcarcinoma_endometriumUterushttps://doi.org/10.1093/nar/gkaa945
V550LUCEC-USUterushttps://doi.org/10.1093/nar/gkaa945
V550LUCECUterushttps://doi.org/10.1093/nar/gkaa945
V550Mcarcinoma_breastBreasthttps://doi.org/10.1093/nar/gkaa945
V550Mcarcinoma_large_intestineLarge Intestinehttps://doi.org/10.1093/nar/gkaa945
V550Mrhabdomyosarcoma_soft_tissueSoft Tissuehttps://doi.org/10.1093/nar/gkaa945
V550Ecarcinoma_lungLunghttps://doi.org/10.1158/2159-8290.CD-12-0095
V550Ecarcinoma_breastBreasthttps://doi.org/10.1158/2159-8290.CD-12-0096
Open in new tab